We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Analysis

Shkreli's Brazen Defiance May Lead To Harsher Sentence

Law360, New York (August 7, 2017, 9:06 PM EDT) -- Public statements from former Turing Pharmaceuticals and Retrophin CEO Martin Shkreli deriding the prosecution’s securities fraud case against him may come back to bite him at sentencing, legal experts said Monday....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.